Division of Transplant Surgery, Department of Surgery, Indiana University School of Medicine, Indianapolis, IN.
Department of Radiology and Imaging Sciences, Indiana University of School of Medicine, Indianapolis, IN.
Transplantation. 2024 Feb 1;108(2):357-368. doi: 10.1097/TP.0000000000004668. Epub 2024 Jan 19.
Although liver transplantation is the gold-standard therapy for end-stage liver disease, the shortage of suitable organs results in only 25% of waitlisted patients undergoing transplants. Three-dimensional (3D) bioprinting is an emerging technology and a potential solution for personalized medicine applications. This review highlights existing 3D bioprinting technologies of liver tissues, current anatomical and physiological limitations to 3D bioprinting of a whole liver, and recent progress bringing this innovation closer to clinical use. We reviewed updated literature across multiple facets in 3D bioprinting, comparing laser, inkjet, and extrusion-based printing modalities, scaffolded versus scaffold-free systems, development of an oxygenated bioreactor, and challenges in establishing long-term viability of hepatic parenchyma and incorporating structurally and functionally robust vasculature and biliary systems. Advancements in liver organoid models have also increased their complexity and utility for liver disease modeling, pharmacologic testing, and regenerative medicine. Recent developments in 3D bioprinting techniques have improved the speed, anatomical, and physiological accuracy, and viability of 3D-bioprinted liver tissues. Optimization focusing on 3D bioprinting of the vascular system and bile duct has improved both the structural and functional accuracy of these models, which will be critical in the successful expansion of 3D-bioprinted liver tissues toward transplantable organs. With further dedicated research, patients with end-stage liver disease may soon be recipients of customized 3D-bioprinted livers, reducing or eliminating the need for immunosuppressive regimens.
虽然肝移植是治疗终末期肝病的金标准疗法,但由于合适器官的短缺,只有 25%的候补患者接受了移植。三维(3D)生物打印是一种新兴技术,也是个性化医疗应用的潜在解决方案。本综述重点介绍了现有的肝脏组织 3D 生物打印技术、3D 生物打印整个肝脏目前在解剖学和生理学方面的局限性,以及使这一创新更接近临床应用的最新进展。我们对 3D 生物打印的多个方面的最新文献进行了综述,比较了激光、喷墨和挤出式打印方式、有支架和无支架系统、开发充氧生物反应器,以及在建立肝实质的长期生存能力和纳入结构和功能强大的脉管系统和胆管系统方面所面临的挑战。肝脏类器官模型的进步也增加了它们在肝脏疾病建模、药物测试和再生医学中的复杂性和实用性。3D 生物打印技术的最新进展提高了 3D 生物打印组织的速度、解剖学和生理学准确性以及生物相容性。重点关注血管系统和胆管的 3D 生物打印优化提高了这些模型的结构和功能准确性,这对于将 3D 生物打印的肝脏组织成功扩展为可移植器官至关重要。通过进一步的专门研究,终末期肝病患者可能很快就能接受定制的 3D 生物打印肝脏,减少或消除对免疫抑制方案的需求。